Structure Therapeutics (NASDAQ:GPCR) Trading 8.3% Higher – Should You Buy?

Structure Therapeutics Inc. (NASDAQ:GPCR) shares traded up 8.3% during mid-day trading on Wednesday . The company traded as high as $30.98 and last traded at $31.11. 414,883 shares traded hands during trading, a decline of 45% from the average session volume of 749,362 shares. The stock had previously closed at $28.71.

Analyst Upgrades and Downgrades

GPCR has been the topic of several recent analyst reports. JMP Securities reissued a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. Finally, Stifel Nicolaus initiated coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price on the stock. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics presently has an average rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Stock Up 4.9 %

The company has a market cap of $1.72 billion, a P/E ratio of -40.83 and a beta of -2.78. The company’s 50-day moving average is $29.75 and its two-hundred day moving average is $35.44.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors have recently added to or reduced their stakes in GPCR. GAMMA Investing LLC boosted its stake in Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after buying an additional 1,122 shares during the period. FNY Investment Advisers LLC purchased a new stake in Structure Therapeutics during the fourth quarter valued at about $40,000. Assetmark Inc. grew its stake in shares of Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after buying an additional 719 shares during the last quarter. Quarry LP purchased a new position in shares of Structure Therapeutics in the second quarter worth about $79,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Structure Therapeutics by 60.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after buying an additional 1,420 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.